Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
This dual-action is what sets tirzepatide apart, making it a compelling alternative for those not achieving desired results with semaglutide
Speak with your GP or a specialist obesity medicine physician about eligibility for ongoing clinical trials
Specifically, retatrutide targets the following receptors: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Glucagon These hormones help regulate hunger, blood sugar and energy use
